Citations

Showing 10 of 108094 citations.

Model for Predicting Breast Cancer Risk in Women With Atypical Hyperplasia
Frank, Ryan D. , Dupont, William D. , Vierkant, Robert A. , Frost, Marlene H., Vachon, Celine M. , Ghosh, Karthik, Carter, Jodi M. , Denison, Lori A., Broderick, Brendan T., Hartmann, Lynn C. , Visscher, Daniel W., Hoskin, Tanya L. , Broderick, Brendan, Radisky, Derek C. , Vierkant, Robert A , Degnim, Amy C. , Winham, Stacey J. , Pankratz, V. Shane , Vachon, Celine M. , Hieken, Tina J. , Carter, Jodi

Mayo Clinic

Journal of Clinical Oncology | April 20, 2018 | Volume: 36 | Issue: 18 | Pages: 1840-1846

10.1200/jco.2017.75.9480 | PMID 29676945 Get It

Purpose Women with atypical hyperplasia (AH) on breast biopsy have an aggregate increased risk of breast cancer (BC), but existing risk prediction models do not provide accurate individualized estimates of risk in this subset of high-risk women. Here, we used the Mayo benign breast disease cohort to develop and validate a model of BC risk prediction that is specifically for women with AH, which we have designated as AH-BC. Patients and Methods Retrospective cohorts of women age 18 to 85 years with pathologically confirmed benign AH from Rochester, MN, and Nashville, TN, were used for model development and external validation, respectively. Clinical risk factors and histologic features of the tissue biopsy were selected using L1-penalized Cox proportional hazards regression. Identified features were included in a Fine and Gray regression model to estimate BC risk, with death as a competing risk. Model discrimination and calibration were assessed in the model-building set and an external validation set. Results The model-building set consisted of 699 women with AH, 142 of whom developed BC (median follow-up, 8.1 years), and the external validation set consisted of 461 women with 114 later BC events (median follow-up, 11.4 years). The final AH-BC model included three covariates: age at biopsy, age at biopsy squared, and number of foci of AH. At 10 years, the AH-BC model demonstrated good discrimination (0.63 [95% CI, 0.57 to 0.70]) and calibration (0.87 [95% CI, 0.66 to 1.24]). In the external validation set, the model showed acceptable discrimination (0.59 [95% CI, 0.51 to 0.67]) and calibration (0.91 [95% CI, 0.65 to 1.42]). Conclusion We have created a new model with which to refine BC risk prediction for women with AH. The AH-BC model demonstrates good discrimination and calibration, and it validates in an external data set.
Growth and alignment of the pediatric subaxial cervical spine following rigid instrumentation and fusion: a multicenter study of the Pediatric Craniocervical Society
Goldstein, Hannah E. , Neira, Justin A., Banu, Matei A. , Aldana, Philipp R. , Braga, Bruno P. , Brockmeyer, Douglas L. , DiLuna, Michael L. , Fulkerson, Daniel H. , Hankinson, Todd C. , Jea, Andrew, Lew, Sean M. , Limbrick, David D. , Martin, Jonathan E. , Rodriguez, Luis F. , Rozzelle, Curtis J. , Tuite, Gerald F. , Wetjen, Nicholas M. , Anderson, Richard C. E. , Limbrick, David D. , Pahys, Joshua M.

Mayo Clinic

Journal of Neurosurgery: Pediatrics | April 20, 2018 | Volume: 22 | Issue: 1 | Pages: 81-88

10.3171/2018.1.peds17551 | PMID 29676682 Get It

OBJECTIVEThe long-term effects of surgical fusion on the growing subaxial cervical spine are largely unknown. Recent cross-sectional studies have demonstrated that there is continued growth of the cervical spine through the teenage years. The purpose of this multicenter study was to determine the effects of rigid instrumentation and fusion on the growing subaxial cervical spine by investigating vertical growth, cervical alignment, cervical curvature, and adjacent-segment instability over time.METHODSA total of 15 centers participated in this multi-institutional retrospective study. Cases involving children less than 16 years of age who underwent rigid instrumentation and fusion of the subaxial cervical spine (C-2 and T-1 inclusive) with at least 1 year of clinical and radiographic follow-up were investigated. Charts were reviewed for clinical data. Postoperative and most recent radiographs, CT, and MR images were used to measure vertical growth and assess alignment and stability.RESULTSEighty-one patients were included in the study, with a mean follow-up of 33 months. Ninety-five percent of patients had complete clinical resolution or significant improvement in symptoms. Postoperative cervical kyphosis was seen in only 4 patients (5%), and none developed a swan-neck deformity, unintended adjacent-level fusion, or instability. Of patients with at least 2 years of follow-up, 62% demonstrated growth across the fusion construct. On average, vertical growth was 79% (4-level constructs), 83% (3-level constructs), or 100% (2-level constructs) of expected growth. When comparing the group with continued vertical growth to the one without growth, there were no statistically significant differences in terms of age, sex, underlying etiology, surgical approach, or number of levels fused.CONCLUSIONSContinued vertical growth of the subaxial spine occurs in nearly two-thirds of children after rigid instrumentation and fusion of the subaxial spine. Failure of continued vertical growth is not associated with the patient’s age, sex, underlying etiology, number of levels fused, or surgical approach. Further studies are needed to understand this dichotomy and determine the long-term biomechanical effects of surgery on the growing pediatric cervical spine.
Repeat-Associated Non-ATG (RAN) Translation in Fuchs' Endothelial Corneal Dystrophy
Soragni, Elisabetta , Petrosyan, Lina, Rinkoski, Tommy A. , Wieben, Eric D. , Baratz, Keith H. , Fautsch, Michael P. , Gottesfeld, Joel M.

Mayo Clinic

Investigative Opthalmology & Visual Science | April 20, 2018 | Volume: 59 | Issue: 5 | Pages: 1888

10.1167/iovs.17-23265 | PMID 29677349 Get It

Ethnic disparity in primary cutaneous CD30+ T‐cell lymphoproliferative disorders: an analysis of 1496 cases from the US National Cancer database
Flowers, Christopher R. , Feldman, Andrew L.

Mayo Clinic

British Journal of Haematology | April 20, 2018 | Volume: 181 | Issue: 6 | Pages: 721-722

10.1111/bjh.15221 | PMID 29676455 Get It

Improving inpatient warfarin therapy safety using a pharmacist-managed protocol
Daniels, Paul R. , Manning, Dennis M., Moriarty, James P. , Bingener-Casey, Juliane, Ou, Narith N., O’Meara, John G. , Roellinger, Daniel , Naessens, James M. , Roellinger, Daniel L

Mayo Clinic

BMJ Open Quality | April 20, 2018 | Volume: 7 | Issue: 2 | Pages: e000290

10.1136/bmjoq-2017-000290 | PMID 29713691 Get It

Introduction Safe management of warfarin in the inpatient setting can be challenging. At the Mayo Clinic hospitals in Rochester, Minnesota, we set out to improve the safety of warfarin management among surgical and non-surgical inpatients. Methods A multidisciplinary team designed a pharmacist-managed warfarin protocol (PMWP) which designated warfarin dosing to inpatient pharmacists with guidance from computerised dosing algorithms. Ordering this protocol was ultimately designed as an ‘opt out’ practice. The primary improvement measure was frequency of international normalised ratio (INR) greater than 5; secondary measures included adoption rate of the protocol, a counterbalance INR metric (INR <1.7 three days after first inpatient warfarin dose), and complication rates, including bleeding and thrombosis events. An interrupted time series analysis was conducted to compare outcomes. Results Among over 50 000 inpatient warfarin recipients, the PMWP was adopted for the majority of both surgical and non-surgical inpatients during the study period (1 January 2005 to 31 December 2011). The primary improvement measure decreased from 5.6% to 3.4% for medical patients and from 5.2% to 2.4% for surgical patients during the preimplementation and postimplementation periods, respectively. The INR counterbalance measure did not change. Postoperative bleeding decreased from 13.5% to 11.1% among surgical patients, but bleeding was unchanged among medical patients. Conclusion Our PMWP led to achievement of improved INR control for inpatient warfarin recipients and to less near-term bleeding among higher risk, surgical patients.
Prognosis and monitoring of giant cell arteritis and associated complications
Kermani, Tanaz A. , Warrington, Kenneth J. , Warrington, Kenneth J

Mayo Clinic

Expert Review of Clinical Immunology | April 20, 2018 | Volume: 14 | Issue: 5 | Pages: 379-388

10.1080/1744666x.2018.1467758 | PMID 29676201 Get It

Biomarkers Associated with Progression of Diabetic Kidney Disease: Do They Hold the Same Meaning for Blacks and Women?
Hickson, LaTonya J. , Jaffe, Allan S. , Rule, Andrew D. , Rule, Andrew D , Hickson, LaTonya J , Balls‐Berry, Joyce E. , Jaffe, Allan S.

Mayo Clinic

Journal of the American Society of Nephrology | April 20, 2018 | Volume: 29 | Issue: 6 | Pages: 1781-1781

10.1681/asn.2017121249 | PMID 29678999 Get It

Prognostic Significance of Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation
O’Brien, Emily C. , Holmes, DaJuanicia N. , Thomas, Laine , Kowey, Peter R. , Singer, Daniel E. , Ezekowitz, Michael D. , Ansell, Jack , Go, Alan S. , Reiffel, James A. , Piccini, Jonathan P. , Fonarow, Gregg C. , Allen, Larry A. , Gersh, Bernard J. , Naccarelli, Gerald V. , Chan, Paul S. , Mahaffey, Kenneth W. , Freeman, James V. , Peterson, Eric D. , Hylek, Elaine M.

Mayo Clinic

Circulation | April 20, 2018 | Volume: 138 | Issue: 9 | Pages: 889-897

10.1161/circulationaha.117.031354 | PMID 29678813 Get It

Background: Bleeding is commonly cited as a reason for stopping oral anticoagulants (OACs). Whether minor bleeding events (nuisance bleeding, NB) in patients with atrial fibrillation on OACs are associated with OAC discontinuation, major bleeding, and stroke/systemic embolism (SSE) is unknown. Methods: Within the ORBIT-AF prospective, outpatient registry (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation), we identified 6771 patients ≥18 years of age at 172 sites with atrial fibrillation and eligible follow-up visits. NB was ascertained from the medical record and was defined as minor bleeding that did not require medical attention (eg, bruising, hemorrhoidal bleeding). We used multivariable pooled logistic regression modeling to evaluate the associations between NB and major bleeding and SSE in the 180 days after documentation of NB. Our unit of analysis was the patient visit, occurring at ≈6-month intervals for a median of 1.5 years following enrollment. Changes in anticoagulation treatment satisfaction after NB were examined descriptively in a subset of patients. Results: The median age of the overall population was 75.0 (interquartile range, 67.0–81.0); 90.0% were white and 42.5% were female. Among 6771 patients (18 560 visits), n=1357 (20.0%) had documented NB, for an incidence rate of 14.8 events per 100 person-years. Over 96.4% of patients remained on OAC therapy after the NB event. Overall, 287 (4.3%) patients experienced major bleeding and 64 (0.96%) had a SSE event during follow-up. NB was not associated with a significant increased risk of major bleeding over 6 months in models adjusting for the ATRIA bleeding score (Anticoagulation and Risk Factors in Atrial Fibrillation) (odds ratio, 1.04; 95% confidence interval, 0.68–1.60; P =0.86). NB was also not associated with increased SSE risk over 6 months in models adjusting for the CHA 2 DS 2 -VASc risk score (odds ratio, 1.24; 95% confidence interval, 0.53–2.91; P =0.62). Conclusions: NB is common among patients with atrial fibrillation on OACs. However, NB was not associated with a higher risk of major bleeding or SSE over the next 6 months, suggesting its occurrence should not lead to changes in anticoagulation treatment strategies in OAC-treated patients. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01165710.
Acute liver failure caused by hepatitis E virus genotype 3 and 4: A systematic review and pooled analysis
Haffar, Samir , Shalimar, S. , Kaur, Ravinder Jeet , Murad, M. Hassan , Bazerbachi, Fateh , Shalimar , Kaur, Ravinder J, Murad, Mohammad H, Bazerbachi, F , Haffar, S , Murad, M Hassan , Wang, Zhen , Prokop, Larry J.

Mayo Clinic

Liver International | April 20, 2018 | Volume: 38 | Issue: 11 | Pages: 1965-1973

10.1111/liv.13861 | PMID 29675889 Get It

AbstractBackground & AimsAcute liver failure caused by hepatitis E virus genotype 3 and 4 has been rarely described. Because of the presence of a short golden therapeutic window in patients with viral acute liver failure from other causes, it is possible that early recognition and treatment might reduce the morbidity and mortality. We performed a systematic review and pooled analysis of acute liver failure caused by hepatitis E virus genotype 3 and 4.MethodsTwo reviewers appraised studies after searching multiple databases on June 12th, 2017. Appropriate tests were used to compare hepatitis E virus genotype 3 vs 4, suspected vs confirmed genotypes, hepatitis E virus‐RNA positive vs negative, and to discern important mortality risk factors.ResultsWe identified 65 patients, with median age 58 years (range: 3‐79), and a male to female ratio of 1.2:1. The median bilirubin, ALT, AST and alkaline phosphatase (expressed by multiplication of the upper limit of normal) levels were 14.8, 45.3, 34.8 and 1.63 respectively. Antihepatitis E virus IgG, antihepatitis E virus IgM and hepatitis E virus‐RNA were positive in 84%, 91% and 86% of patients respectively. The median interval from symptoms onset to acute liver failure was 23 days, and 16 patients underwent liver transplantation. Final outcome was reported in 58 patients and mortality was 46%. Age was a predictor of poor prognosis in multivariate analysis. No important differences were found between patients infected with genotype 3 vs 4, patients with confirmed vs suspected genotypes, or patients with positive vs negative RNA.ConclusionAcute liver failure caused by hepatitis E virus genotype 3 and 4 is rare, similar between genotypes, occurs commonly in middle‐aged/elderly patients and has a very high mortality. Age is predictive of poor prognosis in multivariate analysis.
Depression and Anxiety Among Patients on Chronic Opioid Therapy
Elrashidi, Muhamad Y. , Philpot, Lindsey M. , Ramar, Priya , Leasure, William B. , Ebbert, Jon O. , Philpot, Lindsey M

Mayo Clinic

Health Services Research and Managerial Epidemiology | April 20, 2018 | Volume: 5 | Issue: No issue available | Pages: No page available

10.1177/2333392818771243 | PMID 29761131 Get It

Background: Chronic noncancer pain (CNCP) and chronic opioid therapy (COT) commonly coexist with comorbid depression and anxiety. We investigated the prevalence of depression and anxiety and their correlates at the time of controlled substance agreement (CSA) enrollment among patients with CNCP and a history of depression or anxiety on COT. Methods: Retrospective analysis of 1066 patients in a Midwest primary care practice enrolled in CSAs for COT between May 9, 2013, and August 15, 2016. Patients with self-reported symptoms or a clinical history of depression or anxiety were screened at CSA enrollment using the Patient Health Questionnaire–9 item scale and the Generalized Anxiety Disorder–7 item scale. Results: The percentage of patients screening positive for depression and anxiety at CSA enrollment was 15.4% and 14.4%, respectively. Patients screening positive for depression or anxiety were more likely to be younger, unmarried, unemployed, and live alone compared to patients not screening positive. Patients screening positive for depression or anxiety were more likely to smoke cigarettes and report concern from friends or relatives regarding alcohol consumption. Compared to patients screening negative, patients screening positive for depression had higher odds of receiving opioid doses of ≥50 morphine milligram equivalents per day (adjusted odds ratio: 1.62; 95% confidence interval: 1.01-2.58). Conclusion: Anxiety and depression are prevalent at enrollment in CSAs among patients receiving COT. Future research is needed to determine whether recognition of anxiety and depression leads to improved management and outcomes for this population.